Insys Therapeutics Announces First Patient Enrolled in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol

PHOENIX, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY ) ("Insys" or "the Company") today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM) and is supported by the Canadian Institutes of Health Research (CIHR) and the Company. 

"We are pleased to have begun enrollment in this important trial to treat cocaine dependence, a disease afflicting people in every part of society," said Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer of Insys Therapeutics. "If successful, we anticipate subsequent studies to fully explore the potential of our CBD product as a much needed treatment option for those seeking to overcome their addiction.” 

Dr. Jutras-Aswad, lead investigator for this trial, added, “This is an important investigation for a disorder that causes morbidity, mortality, and has significant social impact. I believe this investigation of CBD for the treatment of cocaine dependence will contribute appreciably toward advancing therapies for the treatment of addiction.” 

The trial is aimed at determining the effects of CBD on the management of craving and withdrawal symptoms, as well as prevention of relapse, helping patients in both the initial stages of treatment, as well as the long-term commitment to remission of their addiction. 

For more information about the trial, see https://clinicaltrials.gov/ct2/show/NCT02559167 .

About Pharmaceutical CBD Cannabidiol (CBD) is one of at least 60 active cannabinoids identified in cannabis and is considered by many to have a wider scope of medical applications than does tetrahydrocannabinol (THC). 

Insys' pharmaceutical CBD is over 99.5% pure cannabidiol. It is synthesized to be chemically identical to the CBD extracted from cannabis and is produced in a controlled environment. The FDA issued a Drug Master File (DMF) to Insys for its CBD active pharmaceutical ingredient in May 2014.

About Cocaine Addiction Cocaine is a powerfully addictive stimulant that is used by approximately 1.5 million Americans. Cocaine addiction has devastating health and social consequences and accounts for over 500,000 emergency visits per year, more than 5,000 deaths per year and significant financial and social burden related to crime, loss of productivity and healthcare costs. Currently, there are no FDA-approved medications to help with the treatment of cocaine addiction or dependence. 

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS ® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS TM (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule.  Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.

SUBSYS ®  and SYNDROS TM are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.

Forward-Looking Statements This press release contains forward-looking statements, including statements regarding: (i) our expectations related to our plan to pursue the development of CBD treatments for cocaine addiction and other addictions, (ii) the potential benefits of our pharmaceutical CBD therapies to patients, (iii) our expectations of addressing unmet needs of patients and the clinical shortcomings of existing commercial products, and (iv) our belief that SYNDROS has distinct advantages over the current formulation of dronabinol in soft gel capsule. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise these statements, except as may be required by law .

Contact: Lisa M. Wilson President, In-Site Communications, Inc. 212-452-2793

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 111

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 81

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 161

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 99

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 210

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 128

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 71

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 126

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 203

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading

Top 5 Most Recently Viewed Articles

Tesla Faces Sales Challenges in Europe Amidst Controversies

Updated Category News Views 428

Tesla's Declining Sales in Key European Markets Tesla Inc (NASDAQ: TSLA) is facing significant sales declines in several European countries as reported in early 2025. These drops, drastic in some cases, seem to be a reflection of growing consumer dissatisfaction linked to CEO Elon Musk's heightened political involvement. The Impact of Elon Musk's Political Engagement As...

Continue Reading
How CareMessage's Wellness Copilot Enhances Diabetes Care

Updated Category News Views 141

Innovative Solutions for Diabetes Care Enhancement CareMessage, a pioneering non-profit organization, recently introduced the Wellness Copilot aimed at transforming diabetes management for vulnerable populations. The initiative comes at a crucial time when many healthcare systems are struggling to meet the demands of an ever-growing diabetic population across the country....

Continue Reading
MEDIROM Healthcare Technologies Announces Major Public Offering

Updated Category News Views 269

MEDIROM Healthcare Technologies Inc. Pricing Public Offering MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) has announced a significant step forward in its growth strategy by pricing a public offering of American Depositary Shares. This offering involves 2,860,000 shares priced at $1.75 each, totaling gross proceeds of around $5,000,000. The company is anticipating...

Continue Reading
Dreame's LEAPTIC Cube: Revolutionizing Action Cameras Today

Updated Category News Views 201

Dreame Unveils the LEAPTIC Cube: The Future of Action Cameras At CES 2026 in Las Vegas, Dreame Technology proudly introduced the LEAPTIC Cube, the company's first 8K AI action camera. This innovative release signifies a remarkable advancement in portable imaging, tailored for content creators, adventurers, and professionals seeking exceptional performance in a compact...

Continue Reading
Two Hands Corporation's Significant Shareholder Meeting Update

Updated Category News Views 294

Two Hands Corporation Reports on Special Meeting Outcomes Two Hands Corporation (CSE: TWOH.X) (OTC: TWOH) recently held a significant special meeting for its shareholders. This gathering served as a platform to discuss vital changes affecting the company's structure and stock distribution. Highlights from the Special Meeting During the meeting, shareholders voted to...

Continue Reading